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Since the earliest days of antiretroviral 
therapy (ART), human immunodefi-
ciency virus (HIV)–positive people, 
those that care for them, and those 
that care about them have hoped for 
the day when HIV infection could be 
cured. The emergence of the first effec-
tive ART combinations was soon fol-
lowed by early efforts to cure infection 
through what became known as “shock 
and kill” therapy. However, direct acti-
vation of HIV-infected cells resulted in 
frightening toxicities. Because of this as 
well as the emerging understanding of 
proviral latency in the 1990s, any con-
sideration of efforts toward an HIV cure 
were viewed as fruitless and even irre-
sponsible in the scientific and medical 
community.
But in 2006, Timothy Brown’s bone 
marrow transplants and cancer treat-
ments resulted in what is still the only 
known HIV cure, as his immune sys-
tem was replaced with cells carrying 
the HIV-resistant Δ32 CCR5 gene. This 
singular event, combined with alternat-
ing waves of hope and frustration in the 
quest for an effective prophylactic HIV 
vaccine and daunting challenges faced 
by societies tasked with the provision of 
life-long ART to populations across the 
globe, galvanized new efforts in the sci-
entific community to reconsider the idea 
of HIV cure.
The National Institutes of Health 
funded 3 groups, the Martin Delaney 
Collaboratories, to work together on HIV 
cure research in 2011. The first demon-
stration of reversal of HIV latency in a 
human study was reported in 2012, and 
the International AIDS Society, led by 
Nobel Laureate Francois Barre-Sinoussi, 
initiated a global effort to galvanize HIV 
cure research in the same year.
In parallel with the accelerating and 
expanding effort in research, HIV cure 
has been much discussed and debated 
in many scientific, public health, and 
social forums in the few years that have 
followed. The goals of these efforts 
have become compartmentalized into 
2 camps. Some doubt that a retroviral 
infection can ever be cleared and thus 
seek an acceptable middle ground: func-
tional cure, a state of autonomous con-
trol of HIV infection without the use of 
ART, in which viremia is undetectable, 
there is no disease progression, immu-
nodeficiency, or HIV transmission, and 
life expectancy is unaltered from those 
without infection. Others seek the erad-
ication of HIV infection altogether and 
an escape both from medical concerns 
and the stigma of an HIV-positive iden-
tity. In truth, it would seem that if suc-
cess is achieved in the near term, it will 
be difficult to tell one outcome from the 
other, and, as with oncological cures, it 
will be difficult to immediately assure 
an individual of the finality of the out-
come. Nevertheless, it is easy to see how 
achieving any progress toward a cure for 
HIV infection could revolutionize the 
management of the pandemic around 
the world and increase the chance of cre-
ating a truly AIDS-free generation.
For this supplemental issue, we invited 
clinicians and scientists who represent 
the newly funded and restructured 
Martin Delaney Collaboratories for HIV 
Cure Research to discuss developments, 
challenges, and priorities in each of 7 
key areas of HIV cure research. These 
discussions are representative of many 
of the advances made in the last few 
years in this nascent field and of the new 
directions under investigation in the 
Collaboratories and other key research 
groups across the globe.
Henrich and colleagues discuss the 
methodological challenges of quantifica-
tion and characterization of the whole-
body burden of replication-competent 
HIV individuals of receiving effective 
ART. The ability to sensitively, specifi-
cally, and precisely measure the size and 
distribution of the cells encoding per-
sistent HIV infection in blood and tis-
sues is a key unmet need that must be 
addressed to allow HIV cure research to 
progress and, ultimately, provide valida-
tion of cures, when achieved.
Mullins and Frenkel highlight the 
recently recognized challenge posed 
by the clonal expansion HIV-1 provi-
rus within HIV-infected cells. Clonally 
expanded cells appear to comprise 
an expanding fraction of the residual 
infected cell population in individuals 
that remain on ART for years, although 
the fraction of these viral genomes 
that can generate a threatening, repli-
cation-competent virus has yet to be 
precisely quantified. Boritz and Douek 
review their recent findings document-
ing the uneven distribution of cell sub-
sets that harbor HIV during ART across 
the blood and tissue compartments. 
They point to the need for studies that 
can reveal the key anatomic sanctuaries 
for persistent infection.
My colleague and collaborator Nancie 
Archin and I  discuss the challenges 
inherent in the development of latency 
reversing agents (LRAs), a key tool to 
reveal persistently infected cells and cre-
ate a window of vulnerability within the 
latent reservoir to allow its targeted clear-
ance. We hope that the steady advances 
in the development of LRAs may soon 
be paired with emerging immunother-
apeutics to clear persistently infected 
cells and allow measurable clinical 
advances toward an HIV cure. In this 
vein, Montaner and Riley review leading 
HIV cure strategies to harness cell-me-
diated control against HIV in stably sup-
pressed ART-treated participants. The 
researchers focus on their efforts to bring 
the antiviral activity of gene-modified T 
cells bearing chimeric antigen receptors 
(CARs), which are resistant to infection, 
to bear as potent tools to clear infection 
or result in a sustained remission in the 
absence of ART.
Ferrari and colleagues focus on other 
immunotherapeutic work engaging 
humoral and innate antiviral immunity 
as tools to clear persistent HIV infec-
tion. Their work focuses on the use of 
HIV-1 Env-specific antibodies that can 
bind the surface of infected CD4+ T 
cells and promote their elimination by 
recruiting cytotoxic effector cells such 
as natural killer cells, monocytes, and 
polymorphonuclear neutrophils cells. 
Finally, Garcia and Silvestri review the 
2 leading animal models under study in 
HIV cure research—humanized mice 
and nonhuman primates—to provide 
much-needed preclinical modeling 
of HIV latency disruption and cure 
strategies.
As with other challenging prob-
lems facing society, the HIV pandemic 
requires a broad, multifaceted approach. 
Among the many important goals for 
future HIV research is the develop-
ment of temporally contained therapies 
capable of achieving an HIV cure, by any 
name. The quest for “a cure” for cancer 
has been undiminished over decades, 
rewarded in recent years with significant 
progress. There is now hope for a future 
in which the risk of acquiring HIV 
infection is reduced by behavioral and 
vaccine approaches; disease progression 
is halted by simple, inexpensive, dura-
ble, and nontoxic ART; innate control 
of HIV infection is improved by novel 
immunotherapies; and eradication of 
infection is possible in a gradually grow-
ing number of people across the world 
with HIV infection.
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